The Plexiform Neurofibroma drugs in development market research report provides comprehensive information on the therapeutics under development for Plexiform Neurofibroma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Plexiform Neurofibroma. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Plexiform Neurofibroma and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Plexiform Neurofibroma by seven companies/universities/institutes. The top development phase for Plexiform Neurofibroma is phase ii with seven drugs in that stage. The Plexiform Neurofibroma pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Plexiform Neurofibroma pipeline products market are: Novartis, Exelixis and Ashvattha Therapeutics.

The key targets in the Plexiform Neurofibroma pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2), Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), and Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1).

The key mechanisms of action in the Plexiform Neurofibroma pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Inhibitor with six drugs in Phase III. The Plexiform Neurofibroma pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Plexiform Neurofibroma pipeline products market including Small Molecule.

Plexiform Neurofibroma overview

Plexiform neurofibromas represent an uncommon variant (30%) of neurofibromatosis type 1 (NF-1) in which neurofibromas arise from multiple nerves as bulging and deforming masses involving also connective tissue and skin folds. These are slow growing, painless, and locally infiltrating tumors. The pattern of inheritance is autosomal dominant and its penetrance is almost complete by 5 years of age.

For a complete picture of Plexiform Neurofibroma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.